Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMMX Immix Biopharma, Inc.

Pre-Market Trading 05-03 09:29:30 EDT

2.31

+0.14

+6.45%

盘前2.37

+0.06+2.60%

08:39 EDT

High2.37	Low2.11	Vol88.13K
Open2.21	D1 Closing2.17	Amplitude11.98%
Mkt Cap60.99M	Tradable Cap32.55M	Total Shares26.40M
T/O199.40K	T/O Rate0.63%	Tradable Shares14.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":2.31,"timestamp":1714680000000,"preClose":2.17,"halted":0,"volume":88130,"hourTrading":{"tag":"盘前","latestPrice":2.37,"preClose":2.31,"latestTime":"08:39 EDT","volume":2,"amount":4.74,"timestamp":1714739958327},"delay":0,"floatShares":14092923,"shares":26404063,"eps":-0.889563,"marketStatus":"Pre-Market Trading","change":0.14,"latestTime":"05-03 09:29:30 EDT","open":2.21,"high":2.37,"low":2.11,"amount":199398.0936,"amplitude":0.119816,"askPrice":2.54,"askSize":53,"bidPrice":2.16,"bidSize":52,"shortable":3,"etf":0,"ttmEps":-0.889563,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1714743000000},"marketStatusCode":1,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":2.31,"preHourTrading":{"tag":"盘前","latestPrice":2.37,"preClose":2.31,"latestTime":"08:39 EDT","volume":2,"amount":4.74,"timestamp":1714739958327},"postHourTrading":{"tag":"盘后","latestPrice":2.31,"preClose":2.31,"latestTime":"16:05 EDT","volume":1,"amount":2.2,"timestamp":1714680337986},"volumeRatio":0.7888570024438699},"requestUrl":"/m/hq/s/IMMX","defaultTab":"news","newsList":[{"id":"2424502588","title":"Immix Biopharma Inc reports results for the quarter ended in December - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2424502588","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2424502588?lang=en_us&edition=fundamental","pubTime":"2024-04-02 23:55","pubTimestamp":1712073341,"startTime":"0","endTime":"0","summary":"* Immix Biopharma Inc    reported a quarterly adjusted loss of 23 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -27 cents.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2423444861","title":"Immix Biopharma Inc    expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2423444861","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2423444861?lang=en_us&edition=fundamental","pubTime":"2024-03-30 04:50","pubTimestamp":1711745405,"startTime":"0","endTime":"0","summary":"* Immix Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on April 1 (estimated) for the period ending December 31 2023   *    * LSEG's mean analyst estimat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422573372","title":"Immix Biopharma Inc    expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2422573372","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2422573372?lang=en_us&edition=fundamental","pubTime":"2024-03-26 04:03","pubTimestamp":1711397001,"startTime":"0","endTime":"0","summary":"* Immix Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on March 27 (estimated) for the period ending December 31 2023   *    * LSEG's mean analyst estima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417141694","title":"Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2417141694","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2417141694?lang=en_us&edition=fundamental","pubTime":"2024-03-05 14:35","pubTimestamp":1709620500,"startTime":"0","endTime":"0","summary":"Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/05/2840587/0/en/Immix-Biopharma-Announces-Be-Proactive-in-AL-AL-Amyloidosis-Awareness-Initiative.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2413421105","title":"Immix Biopharma 12 Month Review Progress Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2413421105","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2413421105?lang=en_us&edition=fundamental","pubTime":"2024-02-21 22:31","pubTimestamp":1708525860,"startTime":"0","endTime":"0","summary":"LOS ANGELES, Feb. 21, 2024  -- Immix Biopharma, Inc., a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.Received U.S. Food and Drug Administration clearance of Investigational New Drug  for NXC-201 treatment of U.S. patients. Received FDA Orphan Drug Designation  for the treatment of AL Amyloidosis. Received FDA Orphan Drug Designation  for the treatment of multiple myeloma. Received EU Orphan Drug Designation  for the treatment of AL Amyloidosis. Heather Landau, MD - Memorial Sloan Kettering Amyloidosis Program Director. Michaela Liedtke, MD - Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center. Suzanne Lentzsch, MD - Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital. Marko Radic, PhD - Autoimmune CAR-T Pioneer and As","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6s.2_eGlVkflCuBx78KjDA--~B/aD0zNzU7dz0xMjExO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/57337275c39e407d905abf969a1a06ad","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6s.2_eGlVkflCuBx78KjDA--~B/aD0zNzU7dz0xMjExO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/57337275c39e407d905abf969a1a06ad"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immix-biopharma-12-month-review-143100470.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2410674640","title":"BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2410674640","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2410674640?lang=en_us&edition=fundamental","pubTime":"2024-02-10 04:15","pubTimestamp":1707509700,"startTime":"0","endTime":"0","summary":"Immix Biopharma , a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, has closed on its previously announced underwritten public offering. The offering consisted of 5,535,055 shares of IMMX common stock, with each share sold at $2.71 per share. Gross proceeds from the offering to ImmixBio are projected to be an estimated $15 million, before standard deductions and expenses. According to the announcement, ImmixBio plans to use funds from the offering for its NXC-201 clinical trials as well as working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22749976","is_publish_highlight":false,"gpt_icon":0},{"id":"2410720643","title":"Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2410720643","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2410720643?lang=en_us&edition=fundamental","pubTime":"2024-02-09 05:45","pubTimestamp":1707428700,"startTime":"0","endTime":"0","summary":"LOS ANGELES, CA, Feb. 08, 2024  -- Immix Biopharma, Inc. , a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today the closing of its previously announced underwritten public offering of 5,535,055 shares of its common stock. Each share of common stock was sold at a price to the public of $2.71 per share. The gross proceeds to ImmixBio from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ImmixBio. The Company intends to use the net proceeds from this offering for NXC-201 clinical trials, working capital and general corporate purposes.Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including sta","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6s.2_eGlVkflCuBx78KjDA--~B/aD0zNzU7dz0xMjExO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/57337275c39e407d905abf969a1a06ad","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6s.2_eGlVkflCuBx78KjDA--~B/aD0zNzU7dz0xMjExO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/57337275c39e407d905abf969a1a06ad"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immix-biopharma-announces-closing-15-214500611.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2409273056","title":"BRIEF-Immix Biopharma Awarded European Union Orphan Drug Designation For Nxc-201 In Al Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2409273056","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2409273056?lang=en_us&edition=fundamental","pubTime":"2024-02-07 23:32","pubTimestamp":1707319953,"startTime":"0","endTime":"0","summary":"Feb 7  - Immix Biopharma Inc   :   * IMMIX BIOPHARMA AWARDED EUROPEAN UNION ORPHAN DRUG DESIGNATION FOR NXC-201 IN AL AMYLOIDOSIS   * IMMIX BIOPHARMA INC - 10 YEARS OF MARKET EXCLUSIVITY ONCE AUTHORIZED IN EU   * IMMIX BIOPHARMA INC - REDUCED FEES FOR EU PROTOCOL ASSISTANCE, MARKETING AUTHORIZATION   * IMMIX BIOPHARMA INC - ACCESS TO EU CENTRALIZED AUTHORIZATION PROCEDURE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409217237","title":"Immix Biopharma Announces New Offering, Sparks Investor Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2409217237","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2409217237?lang=en_us&edition=fundamental","pubTime":"2024-02-07 17:22","pubTimestamp":1707297761,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. (IMMX) has released an update. On February 5, 2024, the Company made headlines by announcing the launch and pricing of its la...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immix-biopharma-announces-new-offering-sparks-investor-interest?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immix-biopharma-announces-new-offering-sparks-investor-interest?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2409217234","title":"Immix Biopharma Signs Definitive $15M Titan Partnership Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2409217234","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2409217234?lang=en_us&edition=fundamental","pubTime":"2024-02-07 17:22","pubTimestamp":1707297745,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. (IMMX) has released an update to notify the public and investors about an entry into a material definitive agreement. Immix B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immix-biopharma-signs-definitive-15m-titan-partnership-deal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immix-biopharma-signs-definitive-15m-titan-partnership-deal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2409065684","title":"PRSO, AKRO and MIRA among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2409065684","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2409065684?lang=en_us&edition=fundamental","pubTime":"2024-02-06 21:37","pubTimestamp":1707226646,"startTime":"0","endTime":"0","summary":"Losers: BioRestorative Therapies  -56%. announces exercise of warrants and issuance of new warrants in a private placement for $8.1 Million gross. Peraso  -32%. Solidion Technology  -20%. Symbotic  -17% after Q1 earnings release. Akero Therapeutics  -16%. Madrigal Pharmaceuticals  -15%.  FMC Corp.  -13% after Q4 earnings release. 89bio  -12% announces inducement grants under Nasdaq listing rule. SenesTech  -8%. Mira Pharmaceuticals  -8%. Hertz Global Holdings  -8% after Q4 earnings release. Immix Biopharma  -7% looks to raise capital to equity offering. TruGolf Holdings  -7%. Scienjoy Holding Corporation  -7%. Chegg  -7% after Q4 earnings release. Guardion Health Sciences  -6%. Viking Therapeutics  -5%.   More on pre-market losers & stocks.  Akero Therapeutics: Deceptively Promising Peraso Inc.  Q3 2023 Earnings Call Transcript IPO Roundup: Amer Sports, FibroBiologics, and more Peraso stock plummets on 1-for-40 reverse stock split Seeking Alpha’s Quant Rating on Akero Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4063092-prso-akro-and-mira-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2409527422","title":"Immix Biopharma Suspends Stock Offering Pending New Prospectus","url":"https://stock-news.laohu8.com/highlight/detail?id=2409527422","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2409527422?lang=en_us&edition=fundamental","pubTime":"2024-02-06 17:57","pubTimestamp":1707213470,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. (IMMX) has released an update. Immix Biopharma, Inc. has halted the offering of its common stock shares under a previously da...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immix-biopharma-suspends-stock-offering-pending-new-prospectus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immix-biopharma-suspends-stock-offering-pending-new-prospectus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2409415548","title":"BRIEF-Immix Biopharma Announces Pricing Of $15 Million Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2409415548","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2409415548?lang=en_us&edition=fundamental","pubTime":"2024-02-06 11:31","pubTimestamp":1707190318,"startTime":"0","endTime":"0","summary":"Feb 5  - Immix Biopharma Inc   :   * IMMIX BIOPHARMA ANNOUNCES PRICING OF $15 MILLION PUBLIC OFFERING OF COMMON STOCK   * IMMIX BIOPHARMA INC - PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF ITS COMMON STOCK AT AN OFFERING PRICE OF $2.71 PER SHARESource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409450568","title":"Immix Biopharma looks to raise capital to equity offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2409450568","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2409450568?lang=en_us&edition=fundamental","pubTime":"2024-02-06 05:01","pubTimestamp":1707166916,"startTime":"0","endTime":"0","summary":"Immix Biopharma  said it intends to offer and sell shares of its common stock in an underwritten public offering.The company said it intends to use the proceedsfor NXC-201 clinical trials, working capital and general corporate purposes.More on Immix Biopharma, Inc.  Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status FDA okays US clinical testing for Immix drug NXC-201","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4062826-immix-biopharma-looks-to-raise-capital-to-equity-offering","is_publish_highlight":false,"gpt_icon":0},{"id":"2409945209","title":"Immix Biopharma to Launch Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2409945209","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2409945209?lang=en_us&edition=fundamental","pubTime":"2024-02-06 04:41","pubTimestamp":1707165660,"startTime":"0","endTime":"0","summary":"Immix Biopharma said it plans to issue shares of its common stock through an underwritten public offering.The clinical-stage biopharmaceutical company on Monday said it intends to use the net proceeds from the proposed offering for its working capital and general corporate purposes, as well as for its NXC-201 clinical trials.Immix Biopharma didn't disclose how many shares it would offer, or the price of each share.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2406341212","title":"Redhill Biopharma, Vera Therapeutics among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2406341212","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2406341212?lang=en_us&edition=fundamental","pubTime":"2024-01-25 23:00","pubTimestamp":1706194805,"startTime":"0","endTime":"0","summary":"Gainers: Processa Pharmaceuticals  +86%. LAVA Therapeutics  +38%. China SXT Pharmaceuticals  +30%. Vera Therapeutics  +28%. Ensysce Biosciences  +20%.  Losers: Redhill Biopharma ADR  -39%. Immix Biopharma  -12%. SciSparc  -12%. Humana HUM -12%. Adagene ADR  -11%.   S&P 500 Health Care Sector -0.34% to 1611.01. Health Care Equipment & Services -0.92% to 1875.74. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.14% to 1317.38.  More on Health Care Select Sector SPDR  Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on Healthcare - BofA’s FMS Healthcare had the largest net buying in five months - Goldman","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4058552-redhill-biopharma-vera-therapeutics-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2406423034","title":"BRIEF-Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved Car-T Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2406423034","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2406423034?lang=en_us&edition=fundamental","pubTime":"2024-01-25 00:07","pubTimestamp":1706112459,"startTime":"0","endTime":"0","summary":"Jan 24  - Immix Biopharma Inc   :   * IMMIX BIOPHARMA STATEMENT ON JANUARY 2024 FDA LABELING CHANGE NOTIFICATION FOR APPROVED CAR-T PRODUCTS   * IMMIX BIOPHARMA INC: IN OUR INTERIM CLINICAL DATA TO DATE, WE HAVE NOT OBSERVED ANY SECONDARY T-CELL MALIGNANCIES   * IMMIX BIOPHARMA INC: BELIEVE CO'S CAR-T CANDIDATES \"WILL CONTINUE TO EXHIBIT A FAVORABLE TOLERABILITY PROFILE MOVING FORWARD\"   * IMMIX BIOPHARMA INC: BELIEVE NXC-201 WILL BE UNIQUELY SUITED TO TREAT AL AMYLOIDOSIS AND OTHER AUTOIMMUNE INDICATIONSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2405170383","title":"RUM, ENVB and GAME among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2405170383","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2405170383?lang=en_us&edition=fundamental","pubTime":"2024-01-24 01:48","pubTimestamp":1706032093,"startTime":"0","endTime":"0","summary":"Gainers: Rail Vision Ltd  +274%. FaZe Holdings  +100%. Nuvve Holding Corp  +50%. Ensysce Biosciences  +48%. Turnstone Biologics Corp  +41%. Rumble  +38%. Sensus Healthcare  +34%. Bit Brother Limited  +31%. Jin Medical International Ltd  +27%.  GameSquare Holdings  +27%.  Losers: Smart for Life  -17%. Aclarion  -15%. Immix Biopharma  -15%. Gyre Therapeutics  -15%. Sezzle  -13%. Brenmiller Energy Ltd  -12%. Recruiter.com Group  -12%. 3M Co.  -12%. Enveric Biosciences  -12%. DatChat  -11%.   More on Mid-day movers & stocks.  Rumble: Scrapping Along The Bottom Rumble: Growing Pains GameSquare Holdings, Inc.  Q3 2023 Earnings Call Transcript Trump SPAC DWAC jumps as DeSantis exits; Rumble spikes on partnership with Barstool Sports Biggest stock movers today: SolarEdge, Spirit Airlines, Chinese EV stocks, and more","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4057494-rum-envb-and-game-among-mid-day-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2392995687","title":"BATL, SNCR and BVN are among pre market gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2392995687","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2392995687?lang=en_us&edition=fundamental","pubTime":"2023-12-18 21:17","pubTimestamp":1702905422,"startTime":"0","endTime":"0","summary":"Getaround (GETR) +85%.Battalion Oil Corp (BATL) +82%.Verrica Pharmaceuticals (VRCA) +62%.Cardio Diagnostics Holdings (CDIO) +45%.Brilliant Acquisition (BRLI) +45%.Northann (NCL) +42%.La Rosa Holdings (LRHC) +32%.BT Brands (BTBD) +31%.Orchestra BioMed Holdings (OBIO) +29%.NCS Multistage Holdings (NCSM) +28%.Synchronoss Technologies (SNCR) +28%.Immix Biopharma (IMMX) +28%.Cuentas (CUEN) +25%.Compania de Minas Buenaventura (BVN) +25%.Studio City International Holdings (MSC) +24%.Ispire Technology (ISPR) +24%.Laser Photonics (LASE) +22%.Cheetah Net Supply Chain Service (CTNT) +21%.GeneDx Holdings (WGS) +20%.Bitdeer Technologies Holding (BTDR) +20%.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4047311-batl-sncr-and-bvn-are-among-pre-market-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2391613095","title":"BATL, BVN and TANH among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2391613095","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2391613095?lang=en_us&edition=fundamental","pubTime":"2023-12-16 02:25","pubTimestamp":1702664740,"startTime":"0","endTime":"0","summary":"Gainers: Getaround  +116%. Battalion Oil Corp  +82%. La Rosa Holdings Corp.  +45%. Verrica Pharmaceuticals  +37%. Bruush Oral Care  +36%. NCS Multistage Holdings  +30%. Brilliant Acquisition Corp  +28%. Compania de Minas Buenaventura  +26%. Immix Biopharma  +24%. Laser Photonics Corp  +22%.Losers: Chanson International Holding  -84%. Inno Holdings  -83%. Maison Solutions  -69%. Aadi Bioscience  -57%. Singlepoint  -45%. Aileron Therapeutics  -38%. Eos Energy Enterprises  -37%. Tantech Holdings Ltd  -36%. TDH Holdings  -28%.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4046958-batl-bvn-and-tanh-among-mid-day-movers","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":0.1},{"period":"1month","weight":-0.2143},{"period":"3month","weight":-0.3873},{"period":"6month","weight":-0.3529},{"period":"1year","weight":-0.1691},{"period":"ytd","weight":-0.6662}],"compareEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0266},{"period":"3month","weight":0.0216},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.0625}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","exchange":"NASDAQ","name":"Immix Biopharma, Inc.","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immix Biopharma, Inc.,IMMX,Immix Biopharma, Inc.股票,Immix Biopharma, Inc.股票老虎,Immix Biopharma, Inc.股票老虎国际,Immix Biopharma, Inc.行情,Immix Biopharma, Inc.股票行情,Immix Biopharma, Inc.股价,Immix Biopharma, Inc.股市,Immix Biopharma, Inc.股票价格,Immix Biopharma, Inc.股票交易,Immix Biopharma, Inc.股票购买,Immix Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction